Lancet Public Health:促进癌症早发现的10大研究重点

2019-10-02 医咖会 医咖会

近日,柳叶刀子刊《The Lancet Public Health》刊登了一篇文章,提出了癌症早期诊断的十大研究重点,关注癌症研究进展的你,不要错过这篇文章!

近日,柳叶刀子刊《The Lancet Public Health》刊登了一篇文章,提出了癌症早期诊断的十大研究重点,关注癌症研究进展的你,不要错过这篇文章!

晚期癌症的诊断与预后不良有关,而癌症早期发现可以为患者提供最大的治愈潜力,在经济上也是更有价值的[PMID:27070711]。这一原则得到了英国癌症研究所“促进癌症早期诊断研究的重大转变”战略的支持。然而目前,研究人员自认为的重要研究问题,与患者和诊疗人员认为的重要研究问题并不匹配[PMID:29062491]。

对患者、诊疗人员、公众成员和专业卫生保健人员开展在线调查和在线投票,并组织了一场16名患者代表和12名卫生保健专业人员组成的研讨会,以确定哪些研究更为重要。

在第一次在线调查中,554名受访者(66%为患者和诊疗人员),共提供了1362条建议,确定了54个独立问题,并与文献对照,以确认所有问题确实尚未定论。涉及7个宽泛的研究主题:健康促进、国家卫生服务过程、新的癌症检测方法、人口特征、筛查(包括风险分层)、症状意识、症状调查。排除了以下研究主题:18岁以下人群,预防,治疗后复发。

第二次在线调查包括241名参与者(70%为患者和诊疗人员),他们对十大研究重点问题进行了排序,并在研讨会上达成了共识,以下为具体的10大研究重点:

1.哪些简单、无创、无痛、经济有效、方便的检测方法可被用于早期检测癌症?

2.血液检测能早期发现部分或全部癌症吗?如何将其纳入常规诊疗中?

3.在全科医疗中增加癌症诊断的检测,会提高癌症早期诊断的患者数量吗?这是否具有成本效益?

4.文化、宗教、性别(包括跨性别者)和行为因素(包括疾病相关的羞耻感)会阻碍患者报告癌症早期症状吗?

5.如何才能有效地利用基因检测来识别个体的癌症发生风险?

6.是否可以使用与癌症相关的诊断工具(如电子病历中的提醒功能)来帮助识别多次出现类似症状的患者?

7.是否可以为目前没有筛查手段的癌症(如淋巴瘤卵巢癌胰腺癌和前列腺癌)研发有效的筛查方法?

8.能否利用已经被诊断为癌症的患者数据寻找出在第一次就诊时被忽视的早期预警信号?

9.促进不同部门和医务人员之间信息共享以提高癌症早期发现的最佳途径是什么?

10.能否更加准确的预测肿瘤是如何发生发展的,这种方法是否可减少不必要的检查和治疗(即过度诊疗)?

这些问题旨在为研究人员、资助机构和企业提供一些方向,以确保未来的癌症早期检测的研究资助和重点可以放在更为重要的问题上。

原始出处:
Ellena Badrick,et al. Top ten research priorities for detecting cancer early. Lancet Public Health. Sep 23, 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1861341, encodeId=20381861341b4, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Aug 07 22:30:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664082, encodeId=f4c6166408263, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Fri Oct 11 01:30:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830274, encodeId=897718302e410, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun May 10 10:30:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621818, encodeId=2fd4162181836, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Oct 04 10:30:00 CST 2019, time=2019-10-04, status=1, ipAttribution=)]
    2020-08-07 shizhenshan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1861341, encodeId=20381861341b4, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Aug 07 22:30:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664082, encodeId=f4c6166408263, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Fri Oct 11 01:30:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830274, encodeId=897718302e410, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun May 10 10:30:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621818, encodeId=2fd4162181836, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Oct 04 10:30:00 CST 2019, time=2019-10-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1861341, encodeId=20381861341b4, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Aug 07 22:30:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664082, encodeId=f4c6166408263, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Fri Oct 11 01:30:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830274, encodeId=897718302e410, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun May 10 10:30:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621818, encodeId=2fd4162181836, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Oct 04 10:30:00 CST 2019, time=2019-10-04, status=1, ipAttribution=)]
    2020-05-10 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1861341, encodeId=20381861341b4, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Aug 07 22:30:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664082, encodeId=f4c6166408263, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Fri Oct 11 01:30:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830274, encodeId=897718302e410, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun May 10 10:30:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621818, encodeId=2fd4162181836, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Oct 04 10:30:00 CST 2019, time=2019-10-04, status=1, ipAttribution=)]

相关资讯

Am J Hum Genet:发现PTEN突变人群潜在标志物:可区分癌症和自闭症

肿瘤抑制基因PTEN的突变可导致多种罕见遗传疾病相关,这些疾病统称为PTEN错构瘤综合征(PHTS)。这类疾病会导致恶性肿瘤发生、行为认知缺陷等,并且不同患者临床表现差异较大,通常很难在早期察觉。而目前还没有一种生物标志物可以预先评估PHTS是否会发展为癌症或者自闭症。

Aging:阜外医院牵头71万癌症患者随访研究:癌症合并高脂血症或有保护作用,合并心衰预后最差

阜外医院杨进刚、袁建松和刘冬等近期发表的一项入选71万患者的大规模队列研究发现,18%的癌症患者有心血管危险因素或心血管疾病,明显高于一般人群。

JAMA Oncol:全新全球癌症数据——来看全球TOP10癌症!

近日,JAMA旗下子刊《JAMA Oncology》在线发表了最新的全球癌症地图,报告了2017年全球范围内195个国家/地区、29组癌症的发病率、死亡率、伤残调整寿命年(DALYs)等数据信息。

JAMA Oncol:免疫治疗前使用抗生素,或显著降低癌症患者的生存率

近日一项研究发现,接受免疫治疗的癌症患者如果近期使用过抗生素的话,病情将更加糟糕,并导致其治疗效果和生存率显着下降。

JAMA Oncology:二甲双胍抗癌实锤!临床试验证实,二甲双胍+靶向药一线治疗,可将携带EGFR突变晚期肺癌患者的生存期延长14个月

一项由墨西哥国立癌症研究所开展的临床II期试验证实,对存在EGFR突变的晚期肺腺癌患者,同时使用二甲双胍和靶向药进行一线治疗,可以将患者的生存期延长14个月!